BRAF and neoplasm: Sorafenib inhibits multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß) that are involved in tumor cell signaling, angiogenesis, and apoptosis (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf, accessed on 1 April 2021).